Market Overview

UPDATE: Jefferies Raises PT on Infinity Pharmaceuticals on IPI-145 Sales Potential

Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

In a report published Wednesday, Jefferies reiterated its Hold rating on Infinity Pharmaceuticals (NASDAQ: INFI), and raised its price target from $21.00 to $41.00.

Jefferies noted, “Wider 4Q12 loss of ~$47M (vs. our loss estimate of ~$29M); cash of $327M at YE12 sufficient into ~2015. With expanding cohorts in Ph1/2a, timing for Ph3 start is likely in ~2014. INFI's rising valuation implies IPI-145 sales potential at >~$3B; however, given evolving competitive field with several promising products well ahead of IPI-145, speedy, comprehensive development strategy is key to realizing its commercial potential.”

Infinity Pharmaceuticals closed on Tuesday at $45.14.

Latest Ratings for INFI

Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral
Oct 2014Stifel NicolausInitiates Coverage onHold

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters